Scientists have synthetically engineered mosquitoes to prevent transmission of dengue virus to humans. This potentially could lead to genetic approaches to controlling the spread of dengue virus among populations.
Browsing: Emerging Disease > Dengue
Take a look at this month’s industry headlines including results for Takeda’s dengue vaccine, approvals for Merck’s Ebola vaccine and the advent of a siderophore antibiotic – the first of this kind.
A team of researchers presented the first large-scale evidence that releasing Wolbachia-infected mosquitoes reduced dengue infections by >70% in high-risk populations.
Take a look at this month’s industry headlines including news on Sanofi’s Dengvaxia® vaccine from the USA and the Philippines, clinical trial results for RSV vaccines and HIV injectables and new acquisitions for Merck.
A review of Venezuela’s current crisis has given cause for concern, highlighting the increased rate of re-emergence and spread of vector-borne diseases such as malaria, Chagas disease, dengue and Zika virus.
Take a look at this month’s industry headlines including an FDA approval for a vaccine protecting against six diseases, positive clinical trial results for bacteraemia and dengue vaccines and new funding for CRSIPR-based antimicrobials.
The US FDA has granted priority review for Sanofi Pasteur’s dengue vaccine, Dengvaxia®, despite its controversial past.
The first citywide deployment of Wolbachia has proved successful, with no dengue cases reported since Wolbachia became established.